Advertisement

Topics

Regeneron Pharmaceuticals, Inc. Company Profile

13:15 EDT 22nd September 2018 | BioPortfolio

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers. Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer. Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.


News Articles [594 Associated News Articles listed on BioPortfolio]

Regeneron Pharmaceuticals Q2 adjusted earnings Beat Estimates

WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) revealed earnings for its second quarter that rose from last year.The company's profit came in at $551 million, or $4.82 per share. This com...

Regeneron Pharmaceuticals, Inc. (REGN) Provides Regulatory Update on EYLEA®

Regeneron Provides Regulatory Update on EYLEA® (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that due to ongoing...

Regeneron Pharmaceuticals, Inc. Strategy, SWOT and Corporate Finance Report [Report Updated: 20062018] Prices from USD $175

Regeneron Pharmaceuticals, Inc. Strategy, SWOT and Corporate Finance ReportSummaryRegeneron Pharmaceuticals, Inc. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company da...

Regeneron Talent Search Doles Out $1.8 Million in Awards to High School Scientists

Training the next generation of scientists is a key for the future of the biotech industry and Regeneron Pharmaceuticals is taking a lead in that responsibility through its sponsorship of the Regenero...

Regeneron, Alnylam partner to discover new treatments for NASH

Regeneron Pharmaceuticals and Alnylam Pharmaceuticals have entered into collaboration to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis (NASH) and potentially ot...

Regeneron collaborates with Zoetis to research antibody therapies for animals

Regeneron Pharmaceuticals, Inc. and Zoetis Inc. today announced a five-year collaboration to research the use of Regeneron's monoclonal antibody therapeutics in animals and discover new veterinary tre...

Regeneron and Alnylam Team up to Tackle NASH Liver Disease

Regeneron Pharmaceuticals and Alnylam Pharmaceuticals signed a collaboration deal to identify RNAi therapies for nonalcoholic steatohepatitis (NASH) and other possibly related liver diseases.

Regeneron grants rilonacept rights to Kiniksa

Regeneron Pharmaceuticals Inc. granted Kiniksa Pharmaceuticals Ltd. exclusive rights to develop and sell rilonacept, an interleukin-1b antagonist, worldwide excluding Israel, Turkey, and select Middle...

Drugs and Medications [272 Associated Drugs and Medications listed on BioPortfolio]

Eylea [Regeneron Pharmaceuticals, Inc.]

These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA. EYLEA (aflibercept) Injection For Intravitreal Injection Ini...

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Arcalyst [Regeneron Pharmaceuticals, Inc.]

These highlights do not include all the information needed to use ARCALYST safely and effectively. See full prescribing information for ARCALYST. ARCALYST (rilonacept)Injection for Subcutaneous UseIni...

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

PubMed Articles [146 Associated PubMed Articles listed on BioPortfolio]

Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes.

To study the safety and efficacy of intravitreal injections of ziv-aflibercept (IVI-ZA) (Zaltrap; Sanofi-Aventis and Regeneron Pharmaceuticals, Tarrytown, NY) during a period of 48 weeks in patients w...

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Post-production handling and administration of protein pharmaceuticals and potential instability issues.

The safety and efficacy of protein pharmaceuticals depend not only on biological activity, but also on purity levels. Impurities may be process related due to limitations in manufacturing, or product ...

Clinical Trials [227 Associated Clinical Trials listed on BioPortfolio]

Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis

Obstructive Sleep Apnea (OSA) is a common disorder with serious consequences that remains underrecognized, with >80% of OSA patients undiagnosed, and undertreated due to inadequate treatme...

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Companies [1333 Associated Companies listed on BioPortfolio]

Regeneron Pharmaceuticals, Inc.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept...

Regeneron Pharmaceuticals

Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candida...

Regeneron

Regeneron has several product candidates progressing through all stages of human clinical trials, for the potential treatment of a diverse set of diseases, including cancer, eye diseases, and inflamma...

ARTEMIS Pharmaceuticals

ARTEMIS Pharmaceuticals, based in Cologne Germany was founded in 1998 and has made significant advances to provide rapid, efficient and sophisticated techniques for the analysis of gene function in ve...

Psychiatric Genomics, Inc.

Dr. C. Anthony Altar is President and Chief Scientific Officer at Psychiatric Genomics. His research team is responsible for gene discovery, medicinal chemistry, and drug discovery efforts. Dr. Altar ...

More Information about "Regeneron Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of Regeneron Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Regeneron Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Regeneron Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Regeneron Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Regeneron Pharmaceuticals, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Gout
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....


Corporate Database Quicklinks



Searches Linking to this Company Record